Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Total Debt: 2014-2024

Historic Total Debt for Zevra Therapeutics (ZVRA) over the last 6 years, with Dec 2024 value amounting to $59.5 million.

  • Zevra Therapeutics' Total Debt rose 4.08% to $61.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61.3 million, marking a year-over-year increase of 4.08%. This contributed to the annual value of $59.5 million for FY2024, which is 39.14% up from last year.
  • As of FY2024, Zevra Therapeutics' Total Debt stood at $59.5 million, which was up 39.14% from $42.8 million recorded in FY2023.
  • Zevra Therapeutics' 5-year Total Debt high stood at $59.5 million for FY2024, and its period low was $781,000 during FY2020.
  • Moreover, its 3-year median value for Total Debt was $42.8 million (2023), whereas its average is $38.4 million.
  • Data for Zevra Therapeutics' Total Debt shows a peak YoY skyrocketed of 234.11% (in 2023) over the last 5 years.
  • Zevra Therapeutics' Total Debt (Yearly) stood at $781,000 in 2020, then reached $12.8 million in 2022, then spiked by 234.11% to $42.8 million in 2023, then spiked by 39.14% to $59.5 million in 2024.